Summary
This prediction ended on 21.09.22 with a price of €18.51. Massive losses of -57.56% were the result for the BUY prediction by Saftman. Saftman has 50% into this predictionEvotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Evotec SE | -30.593% | -30.593% | -44.574% |
| iShares Core DAX® | 1.051% | -1.833% | 12.822% |
| iShares Nasdaq 100 | -0.547% | -3.738% | 40.625% |
| iShares Nikkei 225® | -1.778% | -8.115% | 16.092% |
| iShares S&P 500 | 0.002% | -2.226% | 28.387% |
Comments by Saftman for this prediction
In the thread Evotec AG diskutieren
Saftman hat das Wertpapier Evotec AG in seinem Wikifolio Trendfolge nach Levy gekauft.
In the thread Trading Evotec AG
Die von Saftman gewählte maximale Laufzeit wurde überschritten